Risk factors of drug-induced diseases. Part 1. Classification, non-modified risk factors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Drug-induced diseases (DIDs) have a high prevalence in the population, cause symptoms that force them to seek medical attention or lead to hospitalization, including in the intensive care unit, and a number of DIDs can increase mortality. Some patients are more predisposed to the development of DIDs due to the presence of a number of risk factors. Risk factors for DIDs are divided into general, specific for a particular drug or class of drugs, as well as specific risk factors that increase the risk of developing a particular DIDs. Common risk factors include non-modifiable, partially modifiable and modifiable risk factors. This article describes in detail the most important unmodifiable risk factors, the presence of which increases the likelihood of developing DIDs, as well as examples of their clinical consequences and methods of prevention. Non-modifiable risk factors include: old age, female gender, race, pregnancy, and genetic traits. For effective prevention of the development of DIDs, it is important to assess the presence of risk factors for their development in the patient before taking medications. If unmodifiable risk factors are identified, it is necessary to use all known measures to prevent the development of a potentially possible DIDs, conduct patient education, in addition, careful monitoring of the patient’s condition is very important for the timely detection of a potential DIDs during therapy.

Full Text

Restricted Access

About the authors

D. A Sychev

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

O. D Ostroumova

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

Marina S. Chernyaeva

Central State Medical Academy

Email: doctor@cherniaeva.ru
Cand. Sci. (Med.), Associate Professor of the Department of Internal Medicine and Preventive Medicine Moscow, Russia

A. P Pereverzev

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

A. I Kochetkov

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

T. M Ostroumova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia

M. V Klepikova

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

E. Yu Ebzeeva

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

V. A De

Russian Medical Academy of Continuing Professional Education

Moscow, Russia

References

  1. Tisdale J.E., Miller D.A. (ed.). Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists. 2018. 1399 p.
  2. Сычев Д.А., Остроумова О.Д. и др. Лекарственно-индуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020;27(5):77-84.
  3. Сычев Д.А., Остроумова О.Д., Переверзев А.П. и др. Пожилой и старческий возраст пациентов как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(1):15-24
  4. Сычев Д.А., Остроумова О.Д., Переверзев А.П. и др. Женский пол как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(2):85-94
  5. Сычев Д.А., Остроумова О.Д., Переверзев А.П. и др. Курение как фактор риска развития лекарственно-индуцированных заболеваний. Фарматека. 2021;5:8-16
  6. Сычев Д.А., Остроумова О.Д., Переверзев А.П. и др. Алкоголь как фактор риска лекарственно-индуцированных заболеваний. Качественная клиническая практика. 2021;(2):52-66
  7. Schneeweiss S., Hasford J., Göttler M., et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285-89. doi: 10.1007/s00228-002-0467-0
  8. Schurig A.M., Böhme M., Just K.S., et al. Adverse drug reactions (ADR) and emergencies. The prevalence of suspected ADR in four emergency departments in Germany. Deutsches Arzteblatt international. 2018;115:251-58. Doi: 10.3238/ arztebl.2018.0251.
  9. Wester K., Jönsson A., Spigset O., et al. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiol. Drug Safety 2007;16(2):173-80. doi: 10.1002/pds.1263.
  10. Budnitz D.S., Pollock D.A., Weidenbach K.N., et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Associat. 296(15):1858-66. Doi: 10.1001/ jama.296.15.1858.
  11. Field T.S., Gurwitz J.H., Avorn J., et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161(13):162934. doi: 10.1001/archinte.161.13.1629.
  12. Cooper J.W. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. Southern Med J. 1999;92(5):485-90. doi: 10.1097/00007611-199905000-00007.
  13. Stevenson J.M., Davies J.G., Martin F.C. Medication-related harm: a geriatric syndrome. Age and ageing. 2019;49(1):7-11. doi: 10.1093/ageing/ afz121.
  14. Tannenbaum C., Day D. Sex and age differences impacting pharmacokinetics and pharmacodynamics in human studies. Pharmacol Res. 2017;121:83-93. doi: 10.1016/j. phrs.2017.04.027.
  15. O'Mahony D., O'Sullivan D., Byrne S., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and Ageing. 2015;44(2):213-8. doi: 10.1093/ ageing/afu145.
  16. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-94. doi: 1111/jgs.15767.
  17. Pazan F., Weiss C., Wehling M., FORTA. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(1):61-71. doi: 10.1007/s40266-017-0514-2.
  18. Hanlon J.T., Schmader K.E. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900. doi: 10.1007/s40266-013-0118-4.
  19. Кукес В.Г Клиническая фармакогенетика. М., 2007.
  20. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug metabolism reviews. 2009;41(2):67-76. doi: 10.1080/03602530902722679.
  21. Bowie M.W., Slattum P.W. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263-303. doi: 10.1016/j. amjopharm.2007.10.001.
  22. Blair M.L. Sex-based diferences in physiology: what should we teach in the medical curriculum? Adv Physiol Educat. 2007;31(1):23-5. doi: 10.1152/ advan.00118.2006.
  23. Karlstadt R.G., Hogan D.L., Foxx-Orenstein A. Normal physiology of the gastrointestinal tract and gender diferences. In: Legato M.J., ed. Principles of Gender-Specific Medicine. San Diego: Elsev Acad Press. 2004. Р 377-96. doi: 10.1016/b978-012440905-7/50304-2.
  24. Yanguas-Casas N. Physiological sex diferences in microglia and their relevance in neurological disorders. Neuroimmunol Neuroinflammat. 2020;7:13-22. doi: 10.20517/23478659.2019.31.
  25. Layton A.T., Sullivan J.C. Recent advances in sex differences in kidney function. Am J Physiol Renal Physiol. 2019;316(2):F328-31. doi: 10.1152/ ajprenal.00584.2018.
  26. Mennecozzi M., Landesmann B., Palosaari T, et al. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro? PLoS ONE. 2015;10(4):e0122786. doi: 10.1371/journal. pone.0122786.
  27. Fadiran E.O., Zhang L. Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women. In: Harrison-Woolrych M, editor. Medicines for women. Cham: Springer International Publishing. 2015. Р 41-68.
  28. Chu T. Gender differences in pharmacokinetics. US Pharm. 2014;39(9):40-3.
  29. Moyer A.M., Matey E.T., Miller V.M. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol Res Perspect. 2019;7(6):e00541. doi: 10.1002/prp2.541.
  30. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76(2):215-28. doi: 10.1124/mol.109.056705.
  31. Franconi F., Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171(3):580-94. doi: 10.1111/bph.12362.
  32. Whitley H., Lindsey W. Sex-based differences in drug activity. Am Family Physic. 2009;80(11):1254- 58.
  33. Coleman J.J., McDowell S.E. Ethnicity and adverse drug reactions. Adv Drug React Bull. 2005; 234:899-902.
  34. Eliasson E. Ethnicity and adverse drug reactions. BMJ. 2006;332(7551):1163-4. doi: 10.1136/ bmj.332.7551.1163.
  35. Yasuda S.U., Zhang L., Huang S.M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417-23. doi: 10.1038/ clpt.2008.141.
  36. Ferrell P.B., McLeod H.L. Carbamazepine, HLA-B* 1502andriskofStevens-Johnsonsyndromeandtoxic epidermal necrolysis: US FDA recommendations. Pharmacogenom. 2008;9(10):1543-46. doi: 10.2217/14622416.9.10.1543.
  37. Chung W.H., Hung S.I., Hong H.S., et al. A marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. doi: 10.1038/428486a.
  38. Lonjou C., Thomas L., Borot N., et al. A marker for Stevens-Johnson syndrome; ethnicity matters. Pharmacogenom J. 2006;6(4):265-8. doi: 10.1038/sj.tpj.6500356.
  39. Eliasson E. Ethnicity and adverse drug reactions. BMJ. 2006;332(7551):1163-4. doi: 10.1136/ bmj.332.7551.1163.
  40. Ferrell P.B., McLeod H.L. Carbamazepine, HLA-B* 1502andriskofStevens-Johnsonsyndromeandtoxic epidermal necrolysis: US FDA recommendations. Pharmacogenom. 2008;9(10):1543-6. doi: 10.2217/14622416.9.10.1543.
  41. Hetherington S., Hughes A.R., Mosteller M., et al. Genetic variations in HLA-B region and hypersensitivity to abacavir. Lancet. 2002;359(9312):1121-2. doi: 10.1016/ S0140-6736(02)08158-8.
  42. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-32. doi: 10.1016/s0140-6736(02)07873-x.
  43. McDowell S.E., Coleman J.J., Ferner R.E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177-81. doi: 10.1136/ bmj.38803.528113.55.
  44. Gibbs C.R., Lip G.Y, Beevers D.G. Angioedema due to ACE inhibitors: increased risk in patients of African origin. BrJ Clin Pharmacol. 1999;48(6):861-5. doi: 10.1046/j.1365-2125.1999.00093.x.
  45. Pare G, Kubo M., Byrd J.B., et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genom. 2013;23(9):470-8. doi: 10.1097/ FPC.0b013e328363c137.
  46. Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. Учебное пособие для врачей. 2-е издание, исправленное и дополненное. СПб., 2018. 272 с. [Sychev D.A. Polypharmacy in Clinical Practice: Problem and Solutions. A textbook for doctors. 2nd edition, revised and enlarged. SPb., 2018. 272 р. (In Russ.)].
  47. Gilbert-Barness E. Teratogenic causes of malformations. Ann Clin Lab Sci. 2010;40:99-114.
  48. Ших Е.В. Фармакотерапия во время беременности. Под ред. Е.В. Ших. М., 2020. 208 с.
  49. Moore K.L., Persaud T.VN. The Developing Human: Clinically Oriented Embryology 6th ed. Philadelphia, Pa: WB Saunders Co. 1998. 183 p.
  50. Ушкалова Е.А. Лекарственные средства и беременность. Фарматека. 2003;2:76-87.
  51. Rubin P Drug treatment during pregnancy BMJ. 1998;317:1503-6.
  52. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Reviewer guidance: evaluating the risks of drug exposure in human pregnancies. Washington DC: FDA; 2005.
  53. Koren G., Pariente G. Pregnancy-Associated Changes in Pharmacokinetics and their Clinical Implications. Pharmac Res. 2018;35(3):61. doi: 10.1007/s11095-018-2352-2.
  54. Costantine M.M. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65. doi: 10.3389/fphar.2014.00065.
  55. McGready R., Stepniewska K., Seaton E., et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol. 2003;59(7):553-7. doi: 10.1007/s00228-003-0651-x.
  56. Isoherranen N., Thummel K.E. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab. Disposit: Biol Fate Chem. 2013;41(2):256-doi: 10.1124/dmd.112.050245.
  57. Daly A.K. Pharmacogenomics of adverse drug reactions. Genome Med. 2013;5(1):5. С10.1186/ gm409.
  58. Uetrecht J., Naisbitt D.J. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013;65(2):779-808. doi: 10.1124/ pr. 113.007450.
  59. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437-59. doi: 10.1124/pr.110.003533.
  60. Johnson J.A., Caudle K.E., Gong L., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi: 10.1002/ cpt.668.
  61. Theken K.N., Lee C.R., Gong L., et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi: 10.1002/cpt.1830.
  62. Desta Z., Gammal R.S., Gong L., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy Clin Pharmacol Ther. 2019;106(4):726-33. Doi: 10.1002/ cpt.1477.
  63. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512-18. doi: 10.1161/CIRCULATIONAHA.109.885194.
  64. Scott S.A., Sangkuhl K., Stein C.M., et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 2013;94(3):317-23. doi: 10.1038/ clpt.2013.105.
  65. Lima J.J., Thomas C.D., Barbarino J., et al. Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther 2021;109(6):1417-23. doi: 10.1002/cpt.2015.
  66. Moriyama B., Obeng A.O., Barbarino J., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy Clin Pharmacol Ther. 2017;102(1):45-51. doi: 10.1002/cpt.583.
  67. Hicks J.K., Bishop J.R., Sangkuhl K., et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-34. doi: 10.1002/cpt.147.
  68. Hicks J.K., Sangkuhl K., Swen J., et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi: 10.1002/cpt.597.
  69. Crews K.R., Monte A.A., Huddart R., et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy Clin Pharmacol Ther. 2021;10.1002/cpt.2149. doi: 10.1002/cpt.2149
  70. Amstutz U, Henricks L.M., Offer S.M., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-6. doi: 10.1002/cpt.911
  71. Relling M.V, Schwab M., Whirl-Carrillo M., et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-105. doi: 10.1002/cpt.1304.
  72. Gammal R.S., Court M.H., Haidar C.E., et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-69. doi: 10.1002/cpt.269.
  73. Ramsey L.B., Johnson S.G., Caudle K.E., et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423-28. doi: 10.1038/ clpt.2014.125.
  74. Martin M.A., Hoffman J.M., Freimuth R.R., et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499-500. doi: 10.1038/clpt.2014.38.
  75. Karnes J.H., Rettie A.E., Somogyi A.A., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-9. doi: 10.1002/cpt.2008.
  76. Phillips E.J., Sukasem C., Whirl-Carrillo M., et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018;103(4):574-81. doi: 10.1002/cpt.1004.
  77. Saito Y., Stamp L.K., Caudle K.E., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-7. doi: 10.1002/cpt.161.
  78. McDermott J.H., Wolf J., Hoshitsuki K., et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype. Clin Pharmacol Ther. 2021. doi: 10.1002/cpt.2309.
  79. Gonsalves S.G., Dirksen R.T., Sangkuhl K., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther. 2019;105(6):1338-44. doi: 10.1002/cpt.1319.
  80. Clinical Pharmacogenetics Implementation Consortium: [Electronic resource]. URL: Consortium https://cpicpgx.org (Access date 01.09.2021).
  81. Clinical Pharmacogenetics Implementation Consortium. Guidelines: [Electronic resource]. URL: https://cpicpgx.org/guidelines (Access date 01.09.2021).
  82. Relling M.V., McDonagh E.M., Chang T., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014;96(2):169-74. doi: 10.1038/clpt.2014.97.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies